Dare Bioscience (DARE) Enterprise Value (2013 - 2026)
Dare Bioscience's (DARE) quarterly Enterprise Value came in at -$24.7 million in Q4 2025, down 57.42% YoY from -$58.0 million in Q4 2024, and down 7.09% on a QoQ basis from -$23.1 million in Q3 2025.
Dare Bioscience (DARE) Enterprise Value (2013 - 2026) Analysis & Trends
Dare Bioscience (DARE) has 13 years of Enterprise Value data on file, last reported at -$24.7 million in Q4 2025.
- Quarterly Enterprise Value fell 57.42% year-over-year to -$24.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$24.7 million (down 57.42% YoY) and the FY2025 annual result came in at -$24.7 million, down 57.42% from the prior year.
- Enterprise Value declined to -$24.7 million in Q4 2025, from -$23.1 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$3.6 million in Q1 2024 to a low of -$51.7 million in Q4 2021.
- A 5-year average of -$21.4 million and a median of -$16.1 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2021 — Enterprise Value slumped 1006.64% — and 2024, when it surged 81.61%.
- Tracing DARE's Enterprise Value over 5 years: stood at -$51.7 million in 2021, then soared by 32.91% to -$34.7 million in 2022, then jumped by 69.78% to -$10.5 million in 2023, then plunged by 49.85% to -$15.7 million in 2024, then tumbled by 57.42% to -$24.7 million in 2025.
- The last three Enterprise Value figures came in at -$24.7 million (Q4 2025), -$23.1 million (Q3 2025), and -$5.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - | 2.12 Bn |
| 10 | Dare Bioscience | 12.45 Mn | -166,716.50 | -132,343.00 | -12.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.62 Mn |
| Dec 31, 2025 | -24.71 Mn |
| Sep 30, 2025 | -23.08 Mn |
| Jun 30, 2025 | -5.00 Mn |
| Mar 31, 2025 | -10.33 Mn |
| Dec 31, 2024 | -15.70 Mn |
| Sep 30, 2024 | -11.23 Mn |
| Jun 30, 2024 | -16.41 Mn |
| Mar 31, 2024 | -3.63 Mn |
| Dec 31, 2023 | -10.48 Mn |
| Sep 30, 2023 | -13.89 Mn |
| Jun 30, 2023 | -13.33 Mn |
| Mar 31, 2023 | -19.74 Mn |
| Dec 31, 2022 | -34.67 Mn |
| Sep 30, 2022 | -40.39 Mn |
| Jun 30, 2022 | -32.07 Mn |
| Mar 31, 2022 | -39.32 Mn |
| Dec 31, 2021 | -51.67 Mn |
| Sep 30, 2021 | -45.57 Mn |
| Jun 30, 2021 | -9.11 Mn |